Gutiérrez-Amavizca Bianca Ethel, Gal Andreas, Ortíz-Orozco Rocío, Orth Ulrich, Prado Montes De Oca Ernesto, Gutiérrez-Amavizca Jaime Paul, Figuera Luis E
División de Genética, Centro de Investigación Biomédica de Occidente, IMSS; Doctorado en Genética Humana, Universidad de Guadalajara, Sierra Mojada 800, Col. Independencia, CP. 44340, Guadalajara, Jalisco, México.
J Genet. 2017 Mar;96(1):161-164. doi: 10.1007/s12041-017-0744-4.
Fabry disease (FD) is a lysosomal storage disorder, which develops due to a deficiency in the hydrolytic enzyme, α-galactosidase A (α-Gal A). Alpha-Gal A hydrolyzes glycosphingolipid globotriaosylceramide (Gb3), and an α-Gal A deficiency leads to Gb3 accumulation in tissues and cells in the body. This pathology is likely to involve multiple systems, but it is generally considered to affect primarily vascular endothelium. In this study, we investigated mutations in the GLA gene, which encodes α-Gal A, in Mexican families with FD. We included seven probands with FD that carried known mutations. We analysed pedigrees of the probands, and performed molecular screening in 65 relatives with the potential of carrying a GLA mutation. Five mutations (P40S, IVS4, G328V, R363H, R404del) were detected in seven unrelated Mexican families with the classic FD phenotype. Of the 65 relatives examined, 42 (64.6%) had a GLA gene mutation. In summary, among seven Mexican probands with FD, 65 relatives were at risk of carrying a known GLA mutation, and molecular screening identified 42 individuals with the mutation. Thus, our findings showed that it is important to perform molecular analysis in families with FD to detect mutations and to provide accurate diagnoses for individuals that could be affected.
法布里病(FD)是一种溶酶体贮积症,由于水解酶α-半乳糖苷酶A(α-Gal A)缺乏而发病。α-Gal A可水解糖鞘脂球三糖神经酰胺(Gb3),α-Gal A缺乏会导致Gb3在体内组织和细胞中蓄积。这种病理情况可能累及多个系统,但一般认为主要影响血管内皮。在本研究中,我们调查了墨西哥FD家族中编码α-Gal A的GLA基因的突变情况。我们纳入了7名携带已知突变的FD先证者。我们分析了先证者的家系,并对65名有携带GLA突变可能性的亲属进行了分子筛查。在7个具有典型FD表型的不相关墨西哥家族中检测到5种突变(P40S、IVS4、G328V、R363H、R404del)。在接受检查的65名亲属中,42名(64.6%)有GLA基因突变。总之,在7名患有FD的墨西哥先证者中,65名亲属有携带已知GLA突变的风险,分子筛查鉴定出42名携带该突变的个体。因此,我们的研究结果表明,对FD家族进行分子分析以检测突变并为可能受影响的个体提供准确诊断非常重要。